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Mismatch Repair Deficiency, Microsatellite Instability,
and Survival
An Exploratory Analysis of the Medical Research Council
Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial
Elizabeth C. Smyth, MB, BCh, MSc; AndrewWotherspoon, MD; Clare Peckitt, MSc; David Gonzalez, PhD;
Sanna Hulkki-Wilson, BSc, MSc; Zakaria Eltahir, PhD; Matteo Fassan, MD, PhD; Massimo Rugge, MD, FACG;
Nicola Valeri, MD, PhD; Alicia Okines, MD; Madeleine Hewish, MD, PhD;William Allum, MD; Sally Stenning, MSc;
Matthew Nankivell, MSc; Ruth Langley, MD, PhD; David Cunningham, MD, FMedSci
IMPORTANCE Mismatch repair (MMR) deficiency (MMRD) andmicrosatellite instability (MSI)
are prognostic for survival in many cancers and for resistance to fluoropyrimidines in early
colon cancer. However, the effect of MMRD andMSI in curatively resected gastric cancer
treated with perioperative chemotherapy is unknown.
OBJECTIVE To examine the association amongMMRD, MSI, and survival in patients with
resectable gastroesophageal cancer randomized to surgery alone or perioperative epirubicin,
cisplatin, and fluorouracil chemotherapy in theMedical Research Council Adjuvant Gastric
Infusional Chemotherapy (MAGIC) trial.
DESIGN, SETTING, AND PARTICIPANTS This secondary post hoc analysis of theMAGIC trial
included participants who were treated with surgery alone or perioperative chemotherapy
plus surgery for operable gastroesophageal cancer from July 1, 1994, through April 30, 2002.
Tumor sections were assessed for expression of theMMR proteins mutL homologue 1, mutS
homologue 2, mutS homologue 6, and PMS1 homologue 2. The association amongMSI,
MMRD, and survival was assessed.
MAIN OUTCOMES ANDMEASURES Interaction betweenMMRD andMSI status and overall
survival (OS).
RESULTS Of the 503 study participants, MSI results were available for 303 patients (283 with
microsatellite stability or lowMSI [median age, 62 years; 219males (77.4%)] and 20with high
MSI [median age, 66 years; 14 males (70.0%)]). A total of 254 patients hadMSI andMMR
results available. Patients treated with surgery alone who had highMSI or MMRD had a
median OS that was not reached (95% CI, 11.5 months to not reached) compared with a
median OS among those who had neither highMSI nor MMRD of 20.5 months (95% CI,
16.7-27.8months; hazard ratio, 0.42; 95% CI, 0.15-1.15; P = .09). In contrast, patients treated
with chemotherapy plus surgery who had either highMSI or MMRD had amedian OS of 9.6
months (95% CI, 0.1-22.5 months) compared with a median OS among those whowere
neither highMSI nor MMRD of 19.5 months (95% CI, 15.4-35.2 months; hazard ratio, 2.18;
95% CI, 1.08-4.42; P = .03).
CONCLUSIONS AND RELEVANCE In theMAGIC trial, MMRD and highMSI were associated with
a positive prognostic effect in patients treated with surgery alone and a differentially negative
prognostic effect in patients treated with chemotherapy. If independently validated, MSI or
MMRD determined by preoperative biopsies could be used to select patients for
perioperative chemotherapy.
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G astric cancer is the fifth most common cancer and thethird most common cause of cancer-related deathglobally.1 InWestern countries, patients with operable
gastricorgastroesophagealadenocarcinomafrequentlyundergo
neoadjuvant or perioperative chemotherapy before surgical
resection.2,3This adjunctivechemotherapy is associatedwitha
modestbenefit in termsofoverall survival (OS) comparedwith
surgeryalonebutalsowith toxiceffects, includingneutropenia
andthromboembolicdisease.Unfortunately,afteroptimalmul-
timodality therapy, approximately half of patients undergoing
resectionwill relapse anddie of their cancer. There arenovali-
datedprognosticbiomarkers forpatientswithgastroesophageal
cancerwhoreceiveneoadjuvant treatment, andcurrentpatient
selection is based purely on preoperative radiologic staging.
Microsatellite instability (MSI) andmismatch repair (MMR)
deficiency (MMRD)arepositivelyprognostic for survival inpa-
tients with stage II colon cancer andmay be negatively prog-
nostic for the efficacy of fluoropyrimidine adjuvant chemo-
therapy in the samepatient group.4,5 As a consequence,MMR
protein status assessment is recommended by the National
ComprehensiveCancerNetworkand theEuropeanSociety for
Medical Oncology guidelines for patients with resected stage
II colorectal cancer before adjuvant chemotherapy.6,7 For pa-
tientswithgastric cancer, theprognostic effectofMSIhasbeen
suggested in several studies.8-11 However, these studies are all
retrospective, and each lacked a control group.
The United Kingdom Medical Research Council Adjuvant
Gastric Infusional Chemotherapy (MAGIC) trial was an open-
label, multicenter, phase 3 randomized clinical trial that com-
pared the effect of 6 cycles of perioperative epirubicin, cis-
platin, and infused fluorouracil chemotherapy (3 cycles before
and 3 cycles after resection) plus surgerywith surgery alone in
patients with resectable gastroesophageal cancer.2 Patients
treatedwithperioperativechemotherapyhadimprovedOScom-
paredwithpatients treatedwith surgery alone (5-yearOS, 36%
vs 23%; hazard ratio [HR], 0.75; 95% CI, 0.60-0.93; P = .009).
As a result, perioperative epirubicin, cisplatin, and fluoroura-
cil chemotherapy becameone standard treatment regimen for
patientswithresectablegastroesophagealadenocarcinoma.The
objectives of this work were to establish the proportion of pa-
tientswithhighMSI (MSI-H)orMMRDcancer in theMAGICco-
hort and to evaluatewhether the presence or absence of these
biomarkershadaprognosticeffectonsurvival inpatientstreated
with surgery alone or chemotherapy plus surgery.
Methods
MSI Assessment
This secondary analysis of the MAGIC trial included partici-
pantswhoweretreatedwithsurgeryaloneorperioperativeche-
motherapy plus surgery for operable gastroesophageal can-
cer from July 1, 1994, through April 30, 2002. Genomic DNA
wasextracted frommacrodissected cancer andnoncancer tis-
sueusing theQIAampDNAFFPETissueKit (Qiagen). TheMSI
statuswasdeterminedusing thePromegaMSIAnalysis System
(Promega Corp). A detailed description of the MSI assess-
ment method is in the eMaterial in the Supplement.
Tumorswereclassifiedasmicrosatellite stable (MSS)when
allmarkerswere stable, as having lowMSI (MSI-L) when only
1marker was unstable, and asMSI-Hwithminimum instabil-
ity in 2markers.12 The term instability in this context refers to
the presence of an increased number of nucleotide repeats in
tumor than in thenontumor controlDNA for each sample. The
MSI-L andMSS tumorswere combined for analysis as per pre-
vious analyses in gastric cancer.10,13
MMRProtein Assessment
ForMMRproteinimmunohistochemicalanalysis,3-to4-μmsec-
tionswerepreparedfromthetissuemicroarrayblocksandstained
for themutLhomologue 1 (MLH1),mutShomologue2 (MSH2),
mutShomologue6(MSH6),andPMS1homologue2(PMS2)pro-
teins. The eMaterial in the Supplement provides a detailed de-
scription of the immunohistochemical analysismethod.
Loss of MMR protein expression (MMRD) was desig-
nated when none of the neoplastic epithelial cells had
nuclear staining while positive internal control nuclei (lym-
phocytes and stromal cells) were present in the immediate
vicinity of the tumor infiltrate. Normal expression was
defined as the presence of nuclear staining of tumor cells
irrespective of the proportion or intensity.
Tumor Regression Grading Assessment
Twopathologists(M.F.,M.R.),whoweremaskedtothetreatment
arm,reviewedtheslidesfromallcasesandgradedthepathologic
response using the Mandard tumor regression grading (TRG)
system.14 Differences in opinionwere resolved by discussion.
Statistical Analysis
Overall survivalwascalculated fromsurgery todeath fromany
cause or the last date of follow-up.2 Progression-free survival
was calculated from surgery to the first event (ie, local recur-
rence or progression, distant recurrence, or death from any
cause). Date of surgery was selected as the baseline for bio-
marker analysis to reduce potential bias because only pa-
tients with a surgical specimen were available for inclusion.
Key Points
Question Do patients with operable gastroesophageal cancers
with highmicrosatellite instability have different survival
compared with patients with microsatellite-stable
gastroesophageal cancer when treated with surgery alone or
surgery plus perioperative chemotherapy?
Findings Patients with operable gastroesophageal cancer with
highmicrosatellite instability have superior survival compared with
patients with gastroesophageal cancer with lowmiscrosatellite
instability or microsatellite stable tumors when treated with
surgery alone. However, patients with operable gastroesophageal
cancer with lowmiscrosatellite instability or microsatellite stable
tumors have superior survival compared with patients with
gastroesophageal cancer with highmicrosatellite instability when
treated with perioperative chemotherapy plus surgery.
Meaning Patients with operable gastroesophageal cancer with
highmicrosatellite instability did not benefit from perioperative
chemotherapy. Alternative treatment approaches should be
investigated for these patients.
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Analyses were mainly performed within treatment arms be-
cause of the differences in timing of surgery to reduce poten-
tial bias in theestimatesof effects. Interactionsbetween treat-
mentarmandbiomarkerstatuswereusedtohighlightpotential
differences inprognostic effect andwere assessedusing aCox
proportional hazards regressionmodel. Date of surgery could
not be confirmed for 9patients in the chemotherapyplus sur-
gery arm, and these patientswere excluded from the survival
analyses. Differences in OS by MSI and MMR protein status
were assessedusing theKaplan-Meiermethod and compared
using Cox proportional hazards regression. The Cox propor-
tional hazards regression model was univariate for MSI and
MMRDstatus.AllMMRproteinswereassessed individuallyand
asagroup to includeanyabsentMMRprotein.P < .05wascon-
sidered statistically significant using 2-sided Cox propor-
tional hazards regression. All analyses were conducted using
STATA software, version 14 (StataCorp).
Results
MSI Prevalence and Clinical Characteristics
The MSI results were available for 303 patients (of 456 pa-
tients who had undergone resection). Because the data were
obtained fromresection specimensandanalyses examine sur-
vival from the date of surgery, only patients who had under-
gone surgery (456 of 503 enrolled in the MAGIC trial) are po-
tentially included (eFigure in the Supplement).
No difference was found inmedian survival between pa-
tientswhohad tissue available forMSI analysis and thosewho
didnot (20.7 [95%CI, 17.5-28.3] vs 17.9 [95%CI, 13.5-24.2];HR,
0.91;P < .48). Twentypatients (6.6%)hadMSI-H, and2 (0.7%)
hadMSI-L.The rateofD2 resection inpatientswithMSI-Hwas
55% (vs 41% in the entire MAGIC trial population), and pro-
portions of D2 resections for patients with MSI-H were simi-
lar in both arms. Resections were considered by the surgeon
to be curative in comparable numbers of patients withMSI-H
treated with surgery and surgery plus chemotherapy.
All MSI-H tumors were located in the stomach vs the gas-
troesophageal junctionandesophagus (20 stomachcancers vs
0 gastroesophageal or esophageal tumors, P = .04). A total of
20 of the 234 stomach cancers (8.5%) hadMSI-H (Table 1). The
site of the tumorwasnot prognostic for survival. Patientswith
MSI-H tumors comparedwithMSSorMSI-L tumorsweremore
frequently female and had an older median age. The MSI-H
tumors were more frequently of Lauren intestinal histologic
subtypeand less commonlyhadmetastatic lymphnodes in the
resection specimen. None of these differences were statisti-
callysignificant.Atotalof4(44.4%)of the9patientswithMSI-H
were treatedwithpostoperativechemotherapy,consistentwith
the proportion of patients in the total trial population.
MSI and Pathologic Response to Chemotherapy
No patient with an MSI-H tumor treated with chemotherapy
had a significant pathologic response as measured by a Man-
dard TRG of 1 or 2 (vs 3-5) in the resection specimen. Of
patients with MSS or MSI-L tumors treated with chemo-
therapy, 20 of 123 (16.3%) had a TRG 1 or 2 response (P = .22
for MSI-H vs MSS or MSI-L). The κ between the 2 patholo-
gists for TRG assessment was 0.64, which increased to 0.70
when the TRG was grouped as TRG 1 and 2 (responders) vs
TRG 3 to 5 (nonresponders).
MMRDPrevalence and Clinical Characteristics
Assessment of theMMR protein was performed in 288MLH1
cases, 282MSH2 cases, 281MSH6 cases, and 273 PMS2 cases.
Thedifferent numbers of cases assessable for eachprotein re-
flect exhaustion of tumormaterial in selected tissuemicroar-
rays and resection blocks. All 4 MMR proteins were assess-
able in 268 cases. In 15 of 288 cases (5.2%),MLH1was absent;
PMS2 was absent in 17 of 273 cases (6.2%); MSH2 was absent
in 3 of 282 cases (1.1%); and MSH6 was absent in 2 (0.7%) of
281cases.AssociationwithMMRDwithclinicopathologic char-
acteristics was similar to that for MSI (Table 2).
MMRD and Pathologic Response to Chemotherapy
NopatientwithMMRD cancer treatedwith chemotherapy had
a goodpathologic response to chemotherapy (defined as TRG 1
or TRG 2) comparedwith 14 of 100 patients (14.0%)withMMR
proficiency (MMRP) (P = .36 for comparison of MMRP and
MMRD).
Table 1. Clinicopathologic Characteristics of PatientsWithMSS orMSI-L
vsMSI-Ha
Characteristic
MSS or MSI-L
(n = 283)
MSI-H
(n = 20) P Value
Age, median (IQR) [range], y 62 (54-69)
[23-79]
66 (60-69)
[36-76] .18
Sex
Male 219 (77.4) 14 (70.0)
.42
Female 64 (22.6) 6 (30.0)
Site of tumor
Stomach 214 (75.6) 20 (100)
.04Esophagus 37 (13.1) 0
Gastroesophageal junction 32 (11.3) 0
Histologic subtype
Diffuse 75 (26.5) 2 (10.0)
.25b
Intestinal 163 (57.6) 15 (75.0)
Mixed or other 35 (12.4) 2 (10.0)
Missing 10 (3.5) 1 (5.0)
T stage
T1 12 (4.2) 0
.18b
T2 88 (31.1) 11 (55.0)
T3 169 (59.7) 8 (40.0)
T4 5 (1.8) 0
Missing 8 (2.8) 1 (5.0)
N stage
N negative 54 (19.1) 6 (30.0)
.21bN positive 156 (55.1) 8 (40.0)
Missing 73 (25.8) 6 (30.0)
Abbreviations: IQR, interquartile range; MSI-H, highmicrosatellite stability;
MSI-L, lowmicrosatellite stability; MSS, microsatellite stable.
a Data are presented as number (percentage) of patients unless otherwise
indicated.
b Excluding those with missing data.
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Correlation ofMMRDWithMSI Status
A total of 254 patients had MSI and MMR results available. Of
these, 15 of 17MSI-H tumors hadMMRD detected. Thirteen of
15MLH1-negativetumors (86.7%)withavailableMSIresultshad
MSI-H tumors compared with 4 of 239 MLH1-positive tumors
(1.7%). This finding results in a sensitivity of MLH1 deficiency
testing for MSI prognosis of 76.5% (95% CI, 50.1%-93.2%) and
a specificityof99.2%(95%CI, 97.0%-99.9%).All patientswith
absent MSH2 and MSH6 had MSI-H tumors. Twelve of 16 pa-
tients (75.0%) with absent PMS2 and MSI results had MSI-H
tumors compared with 4 of 236 patients (1.7%) with PMS2-
positive tumors. Overall concordance between MSI-H and
MMRD status was 97.6% (eTable in the Supplement).
Survival Analysis
MSI and Survival
For patients treated with surgery alone, OS was better for pa-
tients with MSI-H than for patients with MSS or MSI-L
because median OS was not reached for patients with MSI-H
(95% CI, 4.4months to not reached), whereas themedian OS
forpatientswithMSSandMSI-Lwas20.3months (95%CI, 16.7-
27.7months;HR,0.35; 95%CI,0.11-1.11;P = .08) (Figure 1). For
patients treatedwith chemotherapyplus surgery,OSwas bet-
ter for patients with MSS or MSI-L (median OS, 22.5 months;
95%CI, 16.1-42.1months),whereasmedianOSforpatientswith
MSI-Hwas9.6months (95%CI,0.1-21.9months;HR,2.22;95%
CI, 1.02-4.85;P = .04) (P = .007for the interactionbetweenMSI
and treatment for OS) (Figure 1).
MMRD and Survival
Patients treatedwith surgery alonewho hadMMRDhad ame-
dian OS that was not reached (95% CI, 4.4 months to not
reached); for patients withMMRP tumors, themedian OSwas
20.7months (95%CI, 17.5-28.6months;HR,0.40;95%CI,0.13-
1.26;P = .12) (Figure2).Patients treatedwithchemotherapyplus
surgery who hadMMRD had amedian OS of 9.7 months (95%
CI,0.2-42.4months); forpatientswithMMRPtreatedwithche-
motherapy, themedianOSwas 20.1months (95%CI, 15.5-35.7
months; HR, 1.62; 95% CI, 0.81-3.26; P = .18) (P = .04 for the
interaction betweenMMR protein status and survival).
MSI and/orMMRD and Survival
Patients treated with surgery alone who had either MSI-H or
MMRDhadbetterOS thandidpatientswhohadneitherMSI-H
nor MMRD; median survival was not reached (95% CI, 11.5
months to not reached) for the MSI-H or MMRD group com-
pared with those who had MSS or MSI-L, who had a median
OS of 20.5 months (95% CI, 16.7-27.8 months; HR, 0.42; 95%
CI,0.15-1.15;P = .09).After treatmentwith chemotherapyplus
surgery, patients who had either MSI-H or MMRD had a me-
dianOSof9.6months (95%CI,0.1-22.5months)comparedwith
those who had neither MSI-H nor MMRD, who had a median
OS of 19.5 months (95% CI, 15.4-35.2 months; HR, 2.18; 95%
CI, 1.08-4.42; P = .03).
Discussion
Our study is the first, to our knowledge, to report the differen-
tiallyprognostic effectsofMSI andMMRproteinexpressionon
survival in a randomized clinical trial with a nonchemo-
therapy control arm for perioperatively treated gastroesopha-
geal cancer. We found that patients with MSI-H or MMRD tu-
morshavesuperior survival comparedwithpatientswithMSS/
MSI-L or MMRP tumors when treated with surgery alone and
converselyhave inferior survival topatientswithMSS/MSI-Lor
MMRP tumors when treated with perioperative chemo-
therapy plus surgery. These findings are significant, because if
validated, theysuggest thatpatientswithMSI-HorMMRDmay
not benefit (ormay experience a detrimental effect) fromperi-
operativechemotherapyandmaybebetter servedbyasurgery-
only approach. BecauseMSI or MMRD tumors comprise up to
10%to20%of stomachcancers in someseries, this findinghas
the potential to affect large numbers of patients.15
Our results are consistent with the results of similar pre-
vious Asian and Western retrospective studies8,10,11,13 that
found a significant positive prognostic effect of MSI-H status
for patients with resected gastric cancer. In our study, MSI-H
and MMRD tumors were only detected in patients with gas-
tric cancer; this finding is commensurate with previous
studies15,16 that found a low prevalence of MSI andMMRD in
gastroesophageal junction and esophageal tumors. The con-
Table 2. Clinicopathologic Characteristics of PatientsWithMMRD
vsMMRPa
Characteristic
MMRP
(n = 246)
MMRD
(n = 22) P Value
Age, median (IQR) [range], y 61 (54-69)
[23-79]
66 (61-68)
[36-76] .19
Sex
Male 190 (77.2) 18 (81.8)
.79
Female 56 (22.8) 4 (18.2)
Site of tumor
Stomach 183 (74.4) 22 (100)
.02Esophagus 34 (13.8) 0
Gastroesophageal junction 29 (11.8) 0
Histologic subtype
Diffuse 67 (27.2) 2 (9.1)
.07b
Intestinal 138 (56.1) 17 (77.3)
Mixed or other 32 (13.0) 1 (4.5)
Missing 9 (3.7) 2 (9.1)
T stage
T1 10 (4.1) 0
.18b
T2 72 (29.3) 11 (50.0)
T3 151 (61.4) 9 (40.9)
T4 5 (2.0) 0
N stage
N negative 51 (20.7) 3 (13.6)
1.00bN positive 135 (54.9) 9 (40.9)
Missing 60 (24.4) 10 (45.5)
Abbreviations: IQR, interquartile range; MMRD, mismatch repair deficiency;
MMRP, mismatch repair proficiency.
a Data are presented as number (percentage) of patients unless otherwise
indicated.
b Excluding those with missing data.
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sistent effect of MSI-H status on prognosis is supported by a
pooled analysis17 of 17 studies that found anHR for OS of 0.76
(95%CI,0.65-0.88;P < .001)and limitedheterogeneity. Incon-
trast, much fewer data are available on the interaction be-
tween MSI status and chemotherapy. In this regard, our re-
sults are comparable to the 2 largest retrospective Asian
studies9,13 inwhichpatientswith resected gastric cancerwere
treated with postoperative fluoropyrimidine chemotherapy.
In these retrospective series, patientswith stage II and IIIMSS
cancer derived a benefit from adjuvant fluorouracil-based
chemotherapy, whereas patients with MSI-H cancer did not.
Although our analysis is post hoc, our study is the first ran-
domized clinical trial, to our knowledge,with a control group
to validate these findings.
In colorectal cancer, theputativeprognostic effectofMMR
protein statuson thebenefit of adjuvant chemotherapy is lim-
ited to patients with stage II disease.5 This finding is hypoth-
esized to be attributable to the relatively small benefit asso-
ciatedwithadjuvant fluoropyrimidine therapy inpatientswith
stage II colorectal cancerandto thepostulatedeffectsofMMRD
on theDNAdamage response to fluoropyrimidines.18First, be-
cause the relative benefit of perioperative chemotherapy for
gastroesophageal cancer is greater than the benefit of adju-
vant chemotherapy in stage II colorectal cancer and second,
because cisplatin and epirubicinwereused in theMAGIC trial
in addition to fluorouracil, our results are possibly unex-
pected (however,becausedataoncompletenodal stagingwere
absent in a substantial percentage of patients, we cannot de-
finitively stage the disease of all patients). One potential ex-
planation for this phenomenon is that the effect ofMMRD on
the DNA damage response to platinum compounds is differ-
ential based on the platinum analog used.19 The MLH1-
deficient cell line models have been reported to be relatively
resistant to cisplatin but not oxaliplatin, which in turn re-
flects the differences in platinum compounds used in the
MAGIC trial and colorectal cancer. This circumvention of the
DNA damage repair mechanism by oxaliplatin may have im-
portant clinical implications; since the MAGIC trial was
presented, oxaliplatin has been determined to be clinically
equivalent to cisplatin andhas replaced it inmanygastric can-
Figure 1. Overall Survival byMicrosatellite Instability (MSI) Status and Treatment Arm in the Study Patients
0
0 1 2 3 4 5 6 7 8 9 10
100
80
60
40
20
Su
rv
iv
al
, %
Time From Surgery, y
129
9
151
10
85
3
100
8
58
1
58
6
42
37
3
27
21
1
22
13
1
15
9
6
7
3
1
1
No. at risk
Chemotherapy and surgery, MSI-negative patients
Chemotherapy and surgery, MSI-positive patients
Surgery, MSI-negative patients
Surgery, MSI-positive patients
Chemotherapy and
surgery, MSS or MSI-L
Chemotherapy and
surgery, MSI-H
Surgery, MSI-H
Surgery, MSS or MSI-L Patients were dichotomized into 2
groups: highMSI (MSI-H) and
microsatellite stable (MSS) or lowMSI
(MSI-L), which are analyzed
separately in each treatment arm.
Differences in overall survival were
assessed using the Kaplan-Meier
method and compared using the
log-rank test. The hazard ratios for
MSI-H vs MSS or MSI-L were 0.35
(95% CI, 0.11-1.11) for surgery alone
(P = .08) and 2.22 (95% CI,
1.02-4.85) for chemotherapy and
surgery (P = .04) (interaction
P = .01). P < .05 was considered to be
statistically significant.
Figure 2. Overall Survival byMismatch Repair (MMR) Protein Status in the Study Patients
0
0 1 2 3 4 5 6 7 8 9 10
100
80
60
40
20
Su
rv
iv
al
, %
Time From Surgery, y
107
12
136
9
73
6
92
8
47
2
52
5
32
2
34
2
19
1
18
1
13
1
13
1
10
8
1
3
6
1
1
1
1
No. at risk
Chemotherapy and surgery, MMRD
Chemotherapy and surgery, MMRP
Surgery, MMRD
Surgery, MMRP
Chemotherapy and
surgery, MMRD
Chemotherapy and
surgery,MMRP
Surgery, MMRP
Surgery, MMRD
Patients were dichotomized into 2
groups: MMR deficiency (MMRD) and
MMR proficiency (MMRP). The
groups are analyzed separately in
each treatment arm. Differences in
overall survival were assessed using
the Kaplan-Meier method and
compared using the log-rank test.
P < .05 was considered to be
statistically significant.
Mismatch Repair Deficiency, Microsatellite Instability, and Survival in theMAGIC Trial Original Investigation Research
jamaoncology.com (Reprinted) JAMAOncology Published online February 23, 2017 E5
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/oncology/0/ by a HEALTH & SOCIAL CARE TRUSTS, N. IRELAND User  on 03/03/2017
Copyright 2017 American Medical Association. All rights reserved.
cer chemotherapy regimens.20 Another hypothesis sidesteps
the requirement for chemoresistance: MSI-H tumors are as-
sociatedwith a vigorous immune infiltrate, whichmay be re-
sponsible for suppression of residual micrometastases after
surgery.21,22 Chemotherapymayhave anegative effect on this
immunosurveillance, thus reducing the innate benefit of the
hypermutated phenotype.
Limitations
A potential limitation of our analysis is that the entireMAGIC
cohortwasnotanalyzedbecausewedidnot receive tissue from
allpatients.This limitationaffects thenumbersanalyzed inour
study.Furthermore, the lowprevalenceofMSI andMMRDand
the number of events limit the statistical reliability of these
data, which as a post hoc analysis should be considered ex-
ploratory.However, because survivalwasnot significantlydif-
ferent in those who did not have tissue available for analysis,
wedonot believe there is a significant bias.Onepotential con-
founderofour results is thatMSIandMMRDtumorsweremore
likely to be of the Lauren intestinal subtype,whichmaybe as-
sociatedwith improved survival outcomes comparedwith the
diffuse subtype.23,24 However, inmultivariate analysis of the
MAGIC trial, histologic subtypewasnot an independent prog-
nostic marker of OS.25 Because we analyzed only resected
specimens that had undergone treatment in the chemo-
therapy arm of the study, to truly determine the prognostic
value of MMRD, evaluation of biopsy specimens is required.
However, there is no evidence that MMRD status changes af-
ter chemotherapy: the equivalent proportion of patientswith
MMRD inboth armsof the trial support this contention. There
is an imperfect correlation between MMRD and MSI assess-
ment in our study. This imperfect correlationmay be a result
of interobserver variability in immunohistochemical analy-
sis assessment, heterogeneity of biomarker expression in gas-
tric cancer, the presence of normally translated but nonfunc-
tionalMMRproteins in the setting of amissenseMLH1 (OMIM
120436)mutation, or other rare genomicdefects that result in
MSI-H status with intact MMRD function, such as the poly-
merase DNA ε1 (POLE) (OMIM 174762) mutation.26-28 Al-
though our overall concordance is high, other studies29,30 in
gastric cancer have found lower sensitivities of MMR protein
immunohistochemical analysis fordetectionofMSI-HMMRD.
For these reasons, a genomic rather than an immunohisto-
chemical approachmay be preferred for patients with gastric
cancer. Finally, analternativehypothesis is that theMSI-Hsta-
tusmightbeassociatedwithothermolecular changes thatpre-
disposepatients tochemotherapyresistance. Inpreclinicalgas-
tric cancer models, epigenetic changes, such as methylation
of bonemorphogenetic protein 4 (BMP4) (OMIM 112262), are
associatedwithplatinumresistance.31Clinicaldata reveal that,
in neoadjuvantly treated patients with gastric cancer, those
with lower levels of promoter gene methylation have im-
proved survival compared with those with more frequent
methylation.32 Promoter methylation ofMLH1 has also been
associated with inferior survival of patients with resected
gastric cancer treated with oxaliplatin-based adjuvant
chemotherapy.33 However, because MSI status is not re-
ported in either of these series, the independent contribution
of epigenetic changes remains unclear.
Conclusions
We report for the first time, to our knowledge, in a random-
ized clinical trial of patients with operable gastroesophageal
cancer treated with chemotherapy with a surgery-only con-
trol group that thepresenceofMMRDisassociatedwithaposi-
tiveprognosticeffect inpatients treatedwithsurgeryaloneand
a differentially negative prognostic effect in patients treated
with chemotherapyplus surgery. If validated, this findinghas
thepotential to improvepatient selection forperioperativeche-
motherapy and spare a significant proportionof patientswith
gastric cancer unnecessary treatment.We do not believe that
thesedata justifyachange inclinicalpractice;however,werec-
ommend prospective trial validation to ascertain the optimal
perioperative treatment for patients with MSI-H gastric can-
cer. In lightof the remarkable successof anti–programmedcell
death protein 1 therapies inMMRDcolorectal cancer, alterna-
tive treatment strategies could be reasonably investigated for
these patients.24
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